타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Vabysmo (faricimab) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Ang-2 / VEGF-A |
Overview Indication | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. |
Positioning Known limitation | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. |
Positioning Development positioning | 1L anti-VEGF alternative |
MoA Mechanism | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. |
MoA Biomarker | OCT central subfield thickness, BCVA, presence of intraretinal fluid. |
Toxicology Major finding | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Toxicology CRS | N/A |
Clinical Safety signal | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Rat |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Vabysmo (faricimab) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Ang-2 / VEGF-A |
Overview Indication | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. |
Positioning Known limitation | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. |
Positioning Development positioning | 1L anti-VEGF alternative |
MoA Mechanism | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. |
MoA Biomarker | OCT central subfield thickness, BCVA, presence of intraretinal fluid. |
Toxicology Major finding | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Toxicology CRS | N/A |
Clinical Safety signal | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Rat |
추천 비교
추천 비교